Correspondence

Multi-vessel Versus Culprit-vessel-only PCI for STEMI: Where Does the Jury Stand?

Talal Almas a,⁎, Ayesha Akram b, Maryam Ehtesham a, Reema Ahmed a, Tarek Khedro a, Uzair Malik b, Lamees Alshaikh c, Lina Alshaikh a, Yasar Sattar c, Hafeez Ul Hassan Virk d

a RCSI University of Medicine and Health Sciences, Dublin, Ireland
b Rawalpindi Medical University, Rawalpindi, Pakistan
c Icahn School of Medicine at Mount Sinai, NY, USA
d Harrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

The annual incidence of myocardial infarctions (MI) in the United States is 1.5 million. Percutaneous coronary intervention (PCI) is a non-surgical procedure whereby a stent is employed to revascularize a blocked coronary vessel. It has become the preferred modality for the treatment of acute ST-segment elevation myocardial infarction (STEMI) [1,2]. In patients presenting with acute coronary syndrome (ACS), the first question that governs the optimal treatment approach is whether there is an obvious culprit lesion for the patient’s underlying presentation. If such a lesion is present alongside ongoing ischemia in a STEMI, emergent PCI of the culprit vessel is recommended. Contrarily, if the culprit lesion is present without ongoing ischemia, the extent of coronary artery disease (CAD) must be evaluated to determine the approach: a single-vessel (PCI of culprit) or multivessel (including the left coronary artery) PCI. The culprit lesion is treated first; however, in patients with multiple coronary artery disease, the distal lesions are treated first. Nevertheless, whether multivessel PCI confers a comparative therapeutic advantage over culprit-vessel-only PCI remains enigmatic.

In 2013, the American College of Cardiology (ACC)/American Heart Association (AHA) discouraged primary PCI of non-culprit vessels in STEMI patients who are hemodynamically stable (class III: harm) [3]. Patients suffering from cardiogenic shock were the only exception in whom emergent revascularization for non-culprit stenoses could be considered, though no evidence substantiating this recommendation was found. Following trials that suggested potential benefit in early non-culprit PCI in stable patients with STEMI, the guidelines were updated to recommend the use of culprit-vessel PCI (CV-PCI) for hemodynamically stable patients. In addition, the guidelines on multivessel PCI (MV-PCI) were updated from class III to class IIb such that it is now recommended for hemodynamically stable patients with multivessel disease during the primary PCI or later as a planned, staged procedure [4]. Although the European Society of Cardiology (ESC) is in corroborating with the ACC/AHA guidelines regarding CV-PCI, there is stronger class IIA evidence supporting MV-PCI during the initial procedure when the STEMI is accompanied by cardiogenic shock or as a planned staged procedure for patients with multivessel disease [5]. Given the fact that 50% of patients presenting with STEMI also have a multivessel disease, MV-PCI and CV-PCI have remained at the epicenter of a cardiology conundrum [5].

Although it has been previously reported that more major adverse cardiovascular events (MACE) are associated with MV-PCI, a meta-analysis published in 2020 comparing the risks of MACE as well as procedural outcomes of MV-PCI and CV-PCI reported inconclusive findings for cardiovascular mortality, all-cause mortality, and procedural complications [6]. The data reported strongly suggests that MV-PCI confers benefit over CV-PCI in patients with STEMI on a background of multivessel disease. Therefore, MV-PCI should be the first-line treatment for this group. Furthermore, in a review of 10 different metaanalyses regarding the use of MV-PCI vs CV-PCI, we conclude that in patients with STEMI, MV-PCI is more efficacious than CV-PCI. A common advantage found among the studies was the reduction in the rates of both revascularization and non-fatal reinfarction with the use of MV-PCI. Additionally, a decrease in MACE was appreciated in the majority of the cases [6–15]. Some of the studies demonstrated no difference in all-cause mortality [10–13]. These findings are delineated in Table 1 below.

In patients with ACS, a key determinant of whether MV-PCI should be performed during the initial procedure depends on the evidence of cardiogenic shock. According to the CULPRIT-SHOCK trial, if there is cardiogenic shock, only the culprit lesion should be treated [16]. If not, simultaneous or staged PCI of other lesions should be considered. The
trial reported that culprit-lesion-only PCI for patients presenting with cardiogenic shock and evidence of multivessel disease on angiography was associated with better outcomes, less all-cause mortality or renal replacement therapy (RRT) at 30 days (45.9%) compared to patients who had an immediate MV-PCI (55.4%) (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.71–0.96, \( p = 0.01 \)).

Additionally, the COMPLETE trial, a randomized, multi-center trial, yields mounting evidence towards the success of MV-PCI in patients with STEMI and multivessel CAD after initial successful culprit-only PCI [17]. A total of 2025 patients were stratified to receive culprit-lesion-only PCI and guideline-directed medical therapy, and another 2016 received complete revascularization in addition to guideline-directed medical therapy. At a median 3-year follow-up, the primary outcomes determined were: (1) composite of cardiovascular (CV) death or new MI or (2) CV death, new MI, or ischemia-driven revascularization (IDR). The results demonstrated that staged MV-PCI reduced MACE in patients with STEMI and CAD [17,18].

Despite its ostensible benefits, single-procedure MV-PCI requires the employment of a higher dose of contrast and radiation in comparison with staged MV-PCI and therefore accentuates the risk of operator-patient fatigue [19]. In patients with complex lesions, it is in most cases optimal to stop and have a full discussion with the patient or family. The optimal treatment modality also depends on whether the site in which the diagnostic angiogram is performed is capable of undergoing PCI, especially in cases requiring complex PCI. In fact, a complicated structural anatomy, such as chronic total occlusion, is the most common anatomical abnormality that can preclude the uptake of PCI [20]. The perplexity of this decision is further compounded when comorbidities such as prior MI and diabetes are present. These considerations need to be taken into account carefully to determine if PCI can be performed safely [20].

In most studies comparing MV-PCI with CV-PCI in the context of STEMI, the clinical benefit conferred by MV-PCI compared to CV-PCI has largely been established. At the same time, however, this superiority may not be the result of complete revascularization itself but of better baseline anatomy and comorbidities compared to the patients who did not undergo complete revascularization. Contrarily, there is less convincing data in patients with NSTEMI and patients with stable ischemic disease. This notion needs to be explored through the means of further trials to better inform the debate on what constitutes the most optimal treatment.

We presume the data we have is sufficient but might be part of a larger picture yet to be fully elucidated!

### Funding

Na.

### Ethical approval

Na.

### Consent

Na.

### Author contribution

TA, AK, ME: conceived the idea, designed the study, and drafted the manuscript. RA, TK, UM: conducted literature search and created the illustrations. LA, LA.: revised the manuscript critically and refined the illustrations. YS, HUHV: revised the final version of the manuscript.

---

**Table 1**

| Sample size | Type of PCI | Risk of repeat revascularization | Major adverse cardiac event (MACE) | Outcome |
|-------------|-------------|---------------------------------|-----------------------------------|---------|
| Levet JY*   | 6751 patients | MV-PCI low rate (3.7% vs 12.3%; RR: 0.33; 95%CI: 0.25 to 0.44) | Reduction in the rate of MACE (13.1% vs 22.1%; RR: 0.54; 95%CI: 0.43 to 0.66) | Inconclusive findings for all-cause mortality, cardiovascular mortality, and procedural complications |
| Garcia DC7  | 1044 patients | CV-PCI higher rate | – | Reduced incidence of non-fatal reinfarctions |
| Feistritzer HJ8 | 6314 patients | MV-PCI lower rate (HR: 0.33, 95% CI: 0.22–0.50, \( p < 0.0001 \)) | – | Reduced incidence of non-fatal reinfarctions |
| Osman M6    | 7423 patients | MV-PCI lower rate (4.0% vs 11.7%, RR: 0.44, 95% CI: 0.28 to 0.70, \( p < 0.0001 \)) | Significant reduction in the rate of MACE (10.7% vs 18.6%, RR: 0.64, 95% CI: 0.51 to 0.81, \( p = 0.002 \)) | – |
| Atti V15   | 7030 patients | MV-PCI lower rate (RR: 0.34; 95% CI: 0.25 to 0.44) | – | Lower risk for reinfarction |
| Rai D13    | 6930 patients | MV-PCI lower rate (RR: 0.36; 95% CI: 0.25–0.53, \( P < 0.0001 \)) | Reduction in the rate of MACE (RR: 0.58, 95% CI: 0.46–0.72, \( P < 0.0001 \)) | Lower risk for reinfarction |
| Dahal K12  | 840 patients | MV-PCI lower rate (RR = 0.35, 0.24–0.52, \( P < 0.0001 \)) | Reduction in the rate of MACE (RR = 0.46, 95% CI: 0.35–0.66, \( P < 0.0001 \)) | Lower risk for reinfarction |
| Vaidya SR13 | 2991 patients | MV-PCI lower rate (RR = 0.38, 95% CI: 0.30–0.47; \( P < 0.00001 \)) | Reduction in the rate of MACE (RR = 0.54, 95% CI: 0.41–0.71; \( P < 0.00001 \)) | No benefit on all-cause mortality and nonfatal MI. |
| VillalbaMencia PA14 | 2006 patients | CV-PCI higher rate (OR: 0.39; 95% CI: 0.30–0.51) | Reduction in the rate of MACE (OR: 0.62; 95% CI: 0.43–0.90) | Lower risk for reinfarction |
| Politi L15  | 263 patients | CV-PCI lower rate | – | Better patient outcome with reduction of non-fatal reinfarction rate |
| CV-PCI higher rate | – | – | – |

Legend. PCI: percutaneous coronary intervention; MV-PCI: Multi-vessel PCI; MACE: Major adverse cardiac event; MI: Myocardial Infarction.
critically and gave the final approval.

Registration of research studies

1. Name of the registry: NA.
2. Unique Identifying number or registration ID: NA.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): NA.

Guarantor

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Talal Almas.

Declaration of competing interest

Na.

References

[1] G. Niccoli, R.A. Montone, B. Ibanez, et al., Optimized treatment of ST-elevation myocardial infarction, Circ. Res. 125 (2) (2019) 245–258, https://doi.org/10.1161/CIRCRESAHA.119.315344.

[2] L. Koltozewski, K.J. Filipiak, J. Kochman, et al., Cost-effectiveness of radial vs. femoral approach in primary percutaneous coronary intervention in STEMI - randomized, control trial, Hellenic J. Cardiol. HJC: HJC – Hellenike kardioi ligike epi theosee 57 (3) (2016) 198–202, https://doi.org/10.1016/j.hjc.2016.06.005.

[3] C. Dejong, R.F. Redberg, Multivessel or culprit vessel-only percutaneous coronary intervention for patients with acute myocardial infarction and cardiogenic shock: real-world evidence in support of CULPRIT-SHOCK, JAMA Intern Med 180 (10) (2020) 1280–1283, https://doi.org/10.1001/jamainternmed.2020.3490.

[4] G. Levine, E. Bates, J. Blankenship, et al., 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, Cathet. Cardiovasc. Interv. 87 (6) (2016) 1001–1019, https://doi.org/10.1002/ccd.26335.

[5] B. Ibanez, S. James, S. Agewall, et al., 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation myocardial infarction of the European Society of Cardiology (ESC), Eur. Heart J. 39 (2) (2018) 119–177, https://doi.org/10.1093/eurheartj/ehx393.

[6] J.Y. Levett, S.B. Windle, K.B. Filion, J. Cabausseb, M.J. Eisenberg, Meta-Analysis of complete versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary disease, Am. J. Cardiol. 135 (2020) 40–49, https://doi.org/10.1016/j.amjcard.2020.08.030.

[7] D.C. Garcia, A.M. Benjo, C.J. White, et al., Meta-analysis of multivessel vs culprit artery only percutaneous coronary intervention in ST elevation myocardial infarction, Ochsner J. 19 (2) (2019) 107–115, https://doi.org/10.31486/ ojv18.0023.

[8] H.J. Friesenrizer, A. John, S. de Waha-Thiele, et al., Multivessel versus culprit-only PCI in STEMI patients with multivessel disease: meta-analysis of randomized controlled trials, Clin. Res. Cardiol. 109 (11) (2020) 1381–1391, https://doi.org/10.1007/s00392-020-01637-6.

[9] M. Osman, S.U. Khan, P.D. Farjo, et al., Meta-analysis comparing complete versus infarct-related artery revascularization in patients with ST-elevation myocardial infarction and multivessel coronary disease, Am. J. Cardiol. 125 (4) (2020) 513–520, https://doi.org/10.1016/j.amjcard.2019.11.017.

[10] V. Atii, Y. Gwon, M.A. Narayan, et al., Multivessel versus culprit-only revascularization in STEMI and multivessel coronary artery disease: meta-analysis of randomized trials, JACC Cardiovasc. Interv. 13 (13) (2020) 1571–1582, https://doi.org/10.1016/j.jcin.2020.09.055.

[11] D. Rai, M.W. Tahir, D. Bandypadhyay, et al., Meta-analysis and trial sequential analysis of randomized controlled trials for multivessel PCI versus culprit artery only PCI in STEMI without cardiogenic shock, Curr. Probl. Cardiol. 46 (3) (2021) 100646, https://doi.org/10.1016/j.cpcardiol.2020.100646.

[12] K. Dahal, J. Rijal, R. Panta, J. Lee, M. Azrin, R. Lootens, Multi-vessel versus culprit-vessel and staged percutaneous coronary intervention in STEMI patients with multivessel disease: a meta-analysis of randomized controlled trials, Cardiovasc. Revascularization Med. 15 (8) (2014) 408–413, https://doi.org/10.1016/j.car rev.2014.10.007.

[13] S.R. Vaidya, A. Qamar, S. Arora, S.R. Devarapally, A. Kondur, P. Kaul, Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials, Coron. Artery Dis. 29 (2) (2018) 151–160, https://doi.org/10.1093/choe/cho005.

[14] P.A. Villalblanca, D.F. Briceno, D. Masera, et al., Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized trials, Int. J. Cardiol. 220 (2016) 251–259, https://doi.org/10.1016/j.ijcard.2016.06.098.

[15] L. Polici, F. Sgura, R. Rossi, et al., A randomised trial of target-vessel versus multives sel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up (published correction appears in Heart. 2014 Feb;100(4):350), Heart 96 (9) (2010) 662–667, https://doi.org/10.1136/hrt.2009.177162.

[16] H. Thiele, D.J. Kumbhani, D.L. Bhatt, Culprit lesion only PCI versus multivessel PCI in cardiogenic shock - culprit-shock, American College of Cardiology (2018), http://www.acc.org/latest-in-cardiology/clinical-trials/2017/10/27/16/10/culpri t-shock. (Accessed 15 April 2021).

[17] S.R. Mehta, D.A. Wood, B. Meeks, et al., Design and rationale of the COMPLETE Trial, J. Am. Coll. Cardiol. 74 (22) (2019) 2713–2723, https://doi.org/10.1016/j.jacc.2019.09.051.

[18] D.A. Wood, J.A. Cairns, J. Wang, et al., Timing of staged nonculprit artery revascularization in patients with ST-segment elevation myocardial infarction: COMPLETE Trial, J. Am. Coll. Cardiol. 74 (22) (2019) 2713–2723, https://doi.org/10.1016/j.jacc.2019.09.051.

[19] H. Cubero-Gallego, R. Romaguera, A. Ariza-Sole, J.A. Gómez-Hospital, A. Cequier, Revascularization strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: urgent or staged? Cardiovasec. Diagn. Ther. 7 (Suppl 2) (2017) S82–S85, https://doi.org/10.21037/cdt.2017.01.15.

[20] C. Casey, D.P. Faxon, Multi-vessel coronary disease and percutaneous coronary intervention, Heart (British Cardiac Society) 90 (3) (2004) 341–346, https://doi.org/10.1136/hrt.2003.018986.